-
公开(公告)号：JP2005162733A
公开(公告)日：2005-06-23
申请号：JP2004228455
申请日：2004-08-04
Applicant: Pfizer Prod Inc , ファイザー・プロダクツ・インク
Inventor： HAGEN TIMOTHY A , HERBIG SCOTT MAX , LO JULIAN BELKNAP , THOMBRE AVINASH GOVIND , APPEL LEAH E , CREW MARSHALL D , DWAYNE THOMAS FREESEN , LYON DAVID K , MCCRAY SCOTT B , WEST JAMES B
IPC: C07H17/00 , A61K9/00 , A61K9/16 , A61K9/20 , A61K31/7052 , A61K47/02 , A61K47/14 , A61K47/18 , A61K47/44 , A61P31/04
CPC classification number: A61K9/1611 , A61K9/143 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K31/7052
Abstract: PROBLEM TO BE SOLVED: To provide an azithromycin preparation form having a bioavailability resembling to that of an instantaneous releasing type azithromycin of the same dose and less gastrointestinal adverse effects. SOLUTION: This azithromycin oral preparation contains an effective amount of an alkalizing agent and azithromycin multiple particles. COPYRIGHT: (C)2005,JPO&NCIPI
Abstract translation: 待解决的问题：提供具有类似于相同剂量的瞬时释放型阿奇霉素的生物利用度的阿奇霉素制剂形式和较少的胃肠道不良作用。 解决方案：这种阿奇霉素口服制剂含有有效量的碱化剂和阿奇霉素多重颗粒。 版权所有（C）2005，JPO＆NCIPI
-
公开(公告)号：JP2010132700A
公开(公告)日：2010-06-17
申请号：JP2010044743
申请日：2010-03-01
Applicant: Pfizer Prod Inc , ファイザー・プロダクツ・インク
Inventor： HAGEN TIMOTHY A , HERBIG SCOTT MAX , LO JULIAN BELKNAP , THOMBRE AVINASH GOVIND , APPEL LEAH E , CREW MARSHALL D , DWAYNE THOMAS FREESEN , LYON DAVID K , MCCRAY SCOTT B , WEST JAMES B
IPC: A61K31/7052 , C07H17/00 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/20 , A61K47/02 , A61K47/14 , A61K47/18 , A61K47/34 , A61K47/44 , A61P31/04 , A61P33/00
CPC classification number: A61K9/1611 , A61K9/143 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K31/7052
Abstract: PROBLEM TO BE SOLVED: To provide an azithromycin dosage form which has bioavailability analogical to an instantly dischargeable azithromycin with the same dose and has gastrointestinal side effect smaller than the bioavailability. SOLUTION: The azithromycin dosage form includes azithromycin multiparticles and an effective amount of an alkalizing agent. Preferably, the alkalizing agent includes an aluminum salt, a magnesium salt, a calcium salt, a bicarbonate, a phosphate, a metal hydroxide, a metal oxide, N-methylglucamine, arginine, an arginine salt, an amine, or a combination thereof. COPYRIGHT: (C)2010,JPO&INPIT
Abstract translation: 要解决的问题：提供具有类似于具有相同剂量的立即可释放的阿奇霉素的生物利用度的阿奇霉素剂型，并且具有小于生物利用度的胃肠道副作用。 解决方案：阿奇霉素剂型包括阿奇霉素多颗粒和有效量的碱化剂。 优选地，碱化剂包括铝盐，镁盐，钙盐，碳酸氢盐，磷酸盐，金属氢氧化物，金属氧化物，N-甲基葡糖胺，精氨酸，精氨酸盐，胺或其组合。 版权所有（C）2010，JPO＆INPIT
-
公开(公告)号：FI935299A0
公开(公告)日：1993-11-29
申请号：FI935299
申请日：1993-11-29
Applicant: PFIZER
Inventor： HERBIG SCOTT M , SMITH KELLY L , VAN EIKEREN PAUL , WEST JAMES B
-
公开(公告)号：DE69322286T2
公开(公告)日：1999-04-22
申请号：DE69322286
申请日：1993-08-12
Applicant: PFIZER
Inventor： HERBIG SCOTT M , SMITH KELLY L , VAN EIKEREN PAUL , WEST JAMES B
-
公开(公告)号：CA2150019C
公开(公告)日：1999-01-05
申请号：CA2150019
申请日：1993-08-12
Applicant: PFIZER
Inventor： HERBIG SCOTT M , WEST JAMES B , VAN EIKEREN PAUL , SMITH KELLY L
Abstract: Supported liquid membrane delivery devices that release a beneficial agent to an aqueous environment following exposure to an environmental trigger. A microporous hydrophobic support membrane at least partially surrounds a beneficial agent-containing hydrophilic formulation. A hydrophobic liquid is held within the microporous support membrane by capillarity and the hydrophobic liquid is substantially permeable to the aqueous environment and the beneficial agent-containing hydrophilic formulation. The entrained hydrophobic liquid becomes substantially permeable to the aqueous environment upon exposure to an environmental trigger such as an enzyme, and the beneficial agent is subsequently released.
-
Patent Agency Ranking
公开(公告)号：FI935299A
公开(公告)日：1994-05-31
申请号：FI935299
申请日：1993-11-29
Applicant: PFIZER
Inventor： HERBIG SCOTT M , SMITH KELLY L , VAN EIKEREN PAUL , WEST JAMES B
-
公开(公告)号：FI112600B
公开(公告)日：2003-12-31
申请号：FI935299
申请日：1993-11-29
Applicant: PFIZER
Inventor： HERBIG SCOTT M , SMITH KELLY L , VAN EIKEREN PAUL , WEST JAMES B
-
公开(公告)号：BG103915A
公开(公告)日：2000-07-31
申请号：BG10391599
申请日：1999-11-23
Applicant: PFIZER
Inventor： AM ENDE MARY T , CURATOLO WILLIAM J , FRIEDMAN HYLAR L , SHANKER RAVI M , HERBIG SCOTT M , FRIESEN DWAYNE T , WEST JAMES B
IPC: A61K9/22 , A61K20060101 , A61K9/00 , A61K9/16 , A61K9/20 , A61K9/26 , A61K9/28 , A61K9/32 , A61K9/50 , A61K9/52 , A61K9/54 , A61K31/135 , A61P3/04 , A61P25/18 , A61P25/24 , A61P25/30 , C07C209/00 , C07C211/42 , C07D20060101
Abstract: The batched forms release sertraline with a speed between 1 and 40 mgA/hr, in the initial period of delay the sertraline is freed with a speed of 1 mgA/hr. The invention also relates to acetate salt, the salts sertraline L-lactate and sertraline L-aspartate, to their pharmaceutically medicamentous forms, to methods for their application for the treatment of different conditions or diseases and to methods for the production of sertraline acetate, sertraline L-lactate and sertraline L-aspartate. 115 claims
-
公开(公告)号：ZA200503812B
公开(公告)日：2006-07-26
申请号：ZA200503812
申请日：2005-05-11
Applicant: PFIZER PROD INC
Inventor： CHIDLAW MARK B , FREISEN DWAYNE T , HERBIG SCOTT M , NIGHTINGALE ALAN S , OKANSEN CYNTHIA A , WEST JAMES B
IPC: A61K20060101 , A61K9/00 , A61K9/20 , A61K9/28 , A61K9/36 , A61K31/137 , A61K31/4985
Abstract: A controlled release delivery composition which can be administered to a high fat use environment such as the human gastrointestinal tract following a high fat meal. The delivery composition is embodied as a core surrounded by an asymmetric polymeric membrane. In a preferred embodiment, the asymmetric polymeric membrane is cellulose acetate.
-
公开(公告)号：BG103918A
公开(公告)日：2000-07-31
申请号：BG10391899
申请日：1999-11-23
Applicant: PFIZER PROD INC
Inventor： FRIESEN DWAYNE T , HERBIG SCOTT M , SHANKER RAVI M , WEST JAMES B
IPC: A61K47/02 , A61K9/00 , A61K9/20 , A61K31/136 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K31/135
Abstract: The invention relates to sertraline containing compositions and a dissolving agent which increases the sertraline solubility in chlorine ion-containing aqueous media. 29 claims
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.02 seconds)
